Susquehanna International Group, LLP Relmada Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$2.3 - $4.36 $28,059 - $53,192	12,200 New	12,200 $39,000
Q4 2023 Feb 14, 2024	BUY	$2.45 - $4.22 $5,635 - $9,706	2,300 Added 9.87%	25,600 $105,000
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $66,464 - $101,572	-26,800 Reduced 53.49%	23,300 $69,000
Q2 2023 Aug 11, 2023	BUY	$2.22 - $3.54 $42,180 - $67,260	19,000 Added 61.09%	50,100 $123,000
Q1 2023 May 16, 2023	BUY	$2.24 - $4.76 $24,192 - $51,408	10,800 Added 53.2%	31,100 $70,000
Q4 2022 Feb 14, 2023	SELL	$2.17 - $35.84 $1.31 Million - $21.6 Million	-602,200 Reduced 96.74%	20,300 $70,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $6.96 Million - $14.1 Million	380,300 Added 157.02%	622,500 $23 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.